Results 111 to 120 of about 1,443,667 (357)

CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

Cancer immunology research, 2020
Antibody agonists that target T-cell costimulatory pathways are being tested in the clinic. FS120, a dual agonist antibody specific for CD137 and OX40, delays tumor growth by improving the activation and proliferation of peripheral T cells. Following the
Miguel Gaspar, J. Pravin, L. Rodrigues, Sandra Uhlenbroich, K. L. Everett, F. Wollerton, Michelle Morrow, M. Tuna, N. Brewis   +8 more
semanticscholar   +1 more source

Bispecific Antibodies Against HIV [PDF]

Cell, 2016
Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire   +3 more sources

Application of humanized mice in the safety experiments of antibody drugs

Animal Models and Experimental Medicine, EarlyView.
The graphical abstract of this review highlights the critical role of humanized mice in the safety evaluation of antibody drugs. First, the inherent immunogenicity of antibody drugs can lead to the production of antidrug antibodies and hypersensitivity reactions on repeated administration.
Zhimin Sun, Mengyun Gu, Zixuan Yang, Lei Shi, Liyuan Zhao, Minhui Zheng, Yan Wang, Wei Zhang, Kexin Han, Naping Tang   +9 more
wiley   +1 more source

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Nature Communications, 2020
T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells to induce tumor cell killing. While TCBs are very potent, on-target off-tumor toxicity remains a challenge when selecting targets. Here, we describe a protease-activated anti-folate receptor
M. Geiger, K. Stubenrauch, J. Sam, W. Richter, Gregor Jordan, J. Eckmann, C. Hage, V. Nicolini, A. Freimoser-Grundschober, Mirko Ritter, M. Lauer, H. Stahlberg, P. Ringler, Jigar Patel, Eric Sullivan, Sandra Grau-Richards, S. Endres, S. Kobold, P. Umaña, P. Brünker, C. Klein   +20 more
semanticscholar   +1 more source

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma. [PDF]

Clin Pharmacol Ther
Epcoritamab is a CD3xCD20 bispecific antibody that activates T cells to kill CD20‐expressing B cells. Epcoritamab is approved for the treatment of adults with different types of relapsed or refractory lymphoma in various geographies, including the United States, Europe, and Japan.
Li T, Gibiansky L, Parikh A, Putnins M, Chiu CW, Sacchi M, Feng H, Ahmadi T, Gupta M, Xu S.   +9 more
europepmc   +2 more sources

Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody‐Dependent Cytotoxicity

Angewandte Chemie International Edition, Accepted Article.
CD59 is an immunomodulatory cell surface receptor associated with human disease. Despite its importance in complement regulation and bacterial pathogenesis, CD59 remains a challenging therapeutic target. Research to date has focused on antibody or protein‐based strategies.
Edward William Tate, Jasmine K. Bickel, Ammar. I. S. Ahmed, Aidan B. Pidd, Rhodri M. Morgan, Tom E. McAllister, Sam M. Horrell, Emma C. Couves, Hemavathi Nagaraj, Edward J. Bartlett, Kamel El Omari, Akane Kawamura, Doryen Bubeck   +12 more
wiley   +1 more source

Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3

Molecular Cancer Therapeutics, 2020
The frequent activation of HER3 signaling as a resistance mechanism to EGFR-targeted therapy has motivated the development of combination therapies that block more than one receptor tyrosine kinase. Here, we have developed a novel tetravalent, bispecific
Alexander Rau, Wolfgang S. Lieb, O. Seifert, Jonas Honer, Dennis Birnstock, F. Richter, Nadine Aschmoneit, Monilola A. Olayioye, R. Kontermann   +8 more
semanticscholar   +1 more source

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy

Cancer Management and Research, 2021
Jie Liang,1 Huihui Zhang,1 Yue Huang,1 Lilv Fan,1 Fanlin Li,1 Min Li,1 Yaping Yan,1 Junshi Zhang,1 Zeyu Li,1 Xuanming Yang1,2 1Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University ...
Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X   +9 more
doaj  

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.

JCI Insight, 2020
Systemic cytokine release and on-target/off-tumor toxicity to normal tissues are the main adverse effects limiting the clinical utility of T cell-redirecting therapies.
K. Staflin, Christina L. Zuch de Zafra, Leah K Schutt, Vanessa L. Clark, Fiona Zhong, Maria Hristopoulos, Robyn Clark, Ji Li, M. Mathieu, Xiaocheng Chen, Jennifer Johnston, J. Low, R. Ybarra, Dionysos Slaga, Jihong Yang, Meric A. Ovacik, N. Dybdal, K. Totpal, M. Junttila, D. Ellerman, Genee Y. Lee, M. Dennis, R. Prell, T. Junttila   +23 more
semanticscholar   +1 more source

Engineering antibodies with cancer‐associated binding sites

BMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian, Yumeng Pan, Yingchun Zhang, Fangling Wang, Zejun Wang   +4 more
wiley   +1 more source